Apollo, great content. Though I want to offer one correction... 100mm shares outstanding is incorrect. There are 55.8mm shares. 100mm might be the amount of authorized shares. The recent slide show you referenced supports my number.
Even with great results Cytodyn will need to make a stronger effort to gain visibility in the market. I don't think the CEO or CFO can accomplish that by themselves. They should hire a savvy Business Development exec to do the talking for them. This stock is so far off the radar that it is tough to compare it with other successful biotech's. Cytodyn could also use an IB like Credit Suisse to get involved and do a roadshow to showcase their IP. A presence like that will validate the science even further. They will do it too because if the IP is valuable enough they will make a killing doing the future underwriting.
It's going to be interesting to see what happens before the end of the year. I have a slight concern they will do a bad financing deal with the likes of a Lincoln Park Capital so they can avoid a reverse split or giving up too much to a partner and get cash in hand before they run out.
News 
Market Data 
Discover 
